Literature DB >> 16966694

Drinking from the fountain of promise: biomarkers in the surveillance of Barrett's oesophagus--the glass is half full!

S L Preston1, J A Jankowski.   

Abstract

Mesh:

Substances:

Year:  2006        PMID: 16966694      PMCID: PMC1856442          DOI: 10.1136/gut.2006.096461

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  28 in total

Review 1.  Phases of biomarker development for early detection of cancer.

Authors:  M S Pepe; R Etzioni; Z Feng; J D Potter; M L Thompson; M Thornquist; M Winget; Y Yasui
Journal:  J Natl Cancer Inst       Date:  2001-07-18       Impact factor: 13.506

2.  TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort.

Authors:  L Murray; A Sedo; M Scott; D McManus; J M Sloan; L J Hardie; D Forman; C P Wild
Journal:  Gut       Date:  2006-05-08       Impact factor: 23.059

3.  p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium.

Authors:  D J Wong; T G Paulson; L J Prevo; P C Galipeau; G Longton; P L Blount; B J Reid
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

Review 4.  Clinical evidence for the adenoma-carcinoma sequence, and the management of patients with colorectal adenomas.

Authors:  J H Bond
Journal:  Semin Gastrointest Dis       Date:  2000-10

5.  Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia.

Authors:  T G Schnell; S J Sontag; G Chejfec; G Aranha; A Metz; S O'Connell; U J Seidel; A Sonnenberg
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

6.  Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.

Authors:  B J Reid; L J Prevo; P C Galipeau; C A Sanchez; G Longton; D S Levine; P L Blount; P S Rabinovitch
Journal:  Am J Gastroenterol       Date:  2001-10       Impact factor: 10.864

Review 7.  Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review.

Authors:  Gareth S Dulai; Sushovan Guha; Katherine L Kahn; Jeffrey Gornbein; Wilfred M Weinstein
Journal:  Gastroenterology       Date:  2002-01       Impact factor: 22.682

8.  Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma.

Authors:  K Bani-Hani; I G Martin; L J Hardie; N Mapstone; J A Briggs; D Forman; C P Wild
Journal:  J Natl Cancer Inst       Date:  2000-08-16       Impact factor: 13.506

9.  Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study.

Authors:  E Montgomery; J R Goldblum; J K Greenson; M M Haber; L W Lamps; G Y Lauwers; A J Lazenby; D N Lewin; M E Robert; K Washington; M L Zahurak; J Hart
Journal:  Hum Pathol       Date:  2001-04       Impact factor: 3.466

10.  Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma.

Authors:  C A Eads; R V Lord; S K Kurumboor; K Wickramasinghe; M L Skinner; T I Long; J H Peters; T R DeMeester; K D Danenberg; P V Danenberg; P W Laird; K A Skinner
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

View more
  2 in total

1.  Predicting Neoplastic Progression in Barrett's Esophagus.

Authors:  Jean S Wang; Marcia I Canto
Journal:  Ann Gastroentol Hepatol       Date:  2010-06

2.  Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.

Authors:  E A Griffiths; S A Pritchard; S M McGrath; H R Valentine; P M Price; I M Welch; C M L West
Journal:  Br J Cancer       Date:  2007-04-17       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.